161 related articles for article (PubMed ID: 36261902)
1. New Indication for Topical Ruxolitnib.
Aschenbrenner DS
Am J Nurs; 2022 Nov; 122(11):21. PubMed ID: 36261902
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo.
Kang C
Drugs; 2024 May; 84(5):579-586. PubMed ID: 38625661
[TBL] [Abstract][Full Text] [Related]
3. JAK inhibitors for the treatment of vitiligo.
Inoue S; Suzuki T; Sano S; Katayama I
J Dermatol Sci; 2024 Mar; 113(3):86-92. PubMed ID: 38326166
[TBL] [Abstract][Full Text] [Related]
4. Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients.
Renert-Yuval Y; Ezzedine K; Grimes P; Rosmarin D; Eichenfield LF; Castelo-Soccio L; Huang V; Desai SR; Walsh S; Silverberg JI; Paller AS; Rodrigues M; Weingarten M; Narla S; Gardner J; Siegel M; Ibad S; Silverberg NB
JAMA Dermatol; 2024 Apr; 160(4):453-461. PubMed ID: 38477910
[TBL] [Abstract][Full Text] [Related]
5. Topical ruxolitinib: A new treatment for vitiligo.
Tavoletti G; Avallone G; Conforti C; Roccuzzo G; Maronese CA; Mattioli MA; Quaglino P; Zalaudek I; Marzano AV; Ribero S; Alberti-Violetti S
J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2222-2230. PubMed ID: 37147856
[TBL] [Abstract][Full Text] [Related]
6. A Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo.
Grossmann MC; Haidari W; Feldman SR
J Drugs Dermatol; 2023 Jul; 22(7):664-667. PubMed ID: 37410047
[TBL] [Abstract][Full Text] [Related]
7. Two cases of vitiligo vulgaris treated with topical Janus kinase inhibitor delgocitinib.
Yagi K; Ishida Y; Otsuka A; Kabashima K
Australas J Dermatol; 2021 Aug; 62(3):433-434. PubMed ID: 33667323
[No Abstract] [Full Text] [Related]
8. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib.
Rothstein B; Joshipura D; Saraiya A; Abdat R; Ashkar H; Turkowski Y; Sheth V; Huang V; Au SC; Kachuk C; Dumont N; Gottlieb AB; Rosmarin D
J Am Acad Dermatol; 2017 Jun; 76(6):1054-1060.e1. PubMed ID: 28390737
[TBL] [Abstract][Full Text] [Related]
9. FDA approves Ruxolitinib (Opzelura) for Vitiligo Therapy: A breakthrough in the field of dermatology.
Sheikh A; Rafique W; Owais R; Malik F; Ali E
Ann Med Surg (Lond); 2022 Sep; 81():104499. PubMed ID: 36147080
[TBL] [Abstract][Full Text] [Related]
10. Utilization of Topical Ruxolitinib in Dermatology: A Review.
Kashetsky N; Turchin I
Skin Therapy Lett; 2023 May; 28(3):8-13. PubMed ID: 37339609
[TBL] [Abstract][Full Text] [Related]
11. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
Rosmarin D; Passeron T; Pandya AG; Grimes P; Harris JE; Desai SR; Lebwohl M; Ruer-Mulard M; Seneschal J; Wolkerstorfer A; Kornacki D; Sun K; Butler K; Ezzedine K;
N Engl J Med; 2022 Oct; 387(16):1445-1455. PubMed ID: 36260792
[TBL] [Abstract][Full Text] [Related]
12. Emerging drugs for the treatment of vitiligo.
Karagaiah P; Valle Y; Sigova J; Zerbinati N; Vojvodic P; Parsad D; Schwartz RA; Grabbe S; Goldust M; Lotti T
Expert Opin Emerg Drugs; 2020 Mar; 25(1):7-24. PubMed ID: 31958256
[No Abstract] [Full Text] [Related]
13. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.
Rosmarin D; Pandya AG; Lebwohl M; Grimes P; Hamzavi I; Gottlieb AB; Butler K; Kuo F; Sun K; Ji T; Howell MD; Harris JE
Lancet; 2020 Jul; 396(10244):110-120. PubMed ID: 32653055
[TBL] [Abstract][Full Text] [Related]
14. Topical Histamine Stimulates Repigmentation of Nonsegmental Vitiligo by a Receptor-Dependent Mechanism.
Liu J; Xu Y; Lin TK; Lv C; Elias PM; Man MQ
Skin Pharmacol Physiol; 2017; 30(3):139-145. PubMed ID: 28419984
[TBL] [Abstract][Full Text] [Related]
15. The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature.
Relke N; Gooderham M
J Cutan Med Surg; 2019; 23(3):298-306. PubMed ID: 30902022
[TBL] [Abstract][Full Text] [Related]
16. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.
Qi F; Liu F; Gao L
Front Immunol; 2021; 12():790125. PubMed ID: 34868078
[TBL] [Abstract][Full Text] [Related]
17. Etiopathogenesis and Emerging Methods for Treatment of Vitiligo.
Iwanowski T; Kołkowski K; Nowicki RJ; Sokołowska-Wojdyło M
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298700
[TBL] [Abstract][Full Text] [Related]
18. JAK-inhibitors in dermatology: current evidence and future applications.
Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
[TBL] [Abstract][Full Text] [Related]
19. Ruxolitinib cream (Opzelura) for nonsegmental vitiligo.
Med Lett Drugs Ther; 2022 Oct; 64(1660):158-159. PubMed ID: 36206166
[No Abstract] [Full Text] [Related]
20. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
